cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
By J. A. Francisco, C. Cerveny, Damon L. Meyer, B. Mixan, K. Klussman, D. Chace, Starr X Rejniak, K. Gordon, R. DeBlanc, B. Toki and 5 more. Blood, 2003
862 citations recorded by the source corpus.
Subfields: Oncology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/e213b5a0a1735ee85f63b1911e0e9960d78c182b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. (2012, background): “When brentuximab vedotin was tested in preclinical models of ALCL, improved activity relative to the unconjugated antibody SGN-30 was observed.(12) The initial phase I clinical trial of brentuximab vedotin was conducted in patients with CD30-positive lymphomas and showed a response rate of 38%, incl”
- Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate (2004, methodology): “specific cytotoxic activity against CD30 expressing cells both in vitro and in vivo (12, 13).”
- Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. (2012, background): “Binding of MMAE to tubulin disrupts the microtubule network, induces cell cycle arrest, and results in apoptotic death of the CD30-expressing tumor cell.(10) In a phase I study that enrolled 45 patients with relapsed or refractory CD30-positive lymphomas, the maximally tolerated dose of brentuximab ”